October 22, 2018 / 6:16 AM / 23 days ago

BRIEF-Cantargia: Positive Phase I Data With Lead Candidate CAN04 At ESMO

Oct 22 (Reuters) - Cantargia AB:

* PRESENTED ON SATURDAY POSITIVE PHASE I CLINICAL DATA WITH LEAD CANDIDATE CAN04 AT ESMO

* SAID ANTIBODY CAN04 WAS WELL TOLERATED AND 6 MG/KG IS A SAFE DOSE

* EFFECTS ON BIOMARKERS AND 5 OF 13 EVALUABLE PATIENTS ACHIEVED STABLE DISEASE

* 10 MG/KG CURRENTLY INVESTIGATED BEFORE START OF PHASE IIA DURING Q4 2018

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below